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Abstract
Background: Although direct-acting antivirals can achieve sustained virological response rates greater than
90% in Hepatitis C Virus (HCV) infected persons, at present the majority of HCV-infected individuals remain
undiagnosed and therefore untreated. While there are a wide range of HCV serological tests available, there is a
lack of formal assessment of their diagnostic performance. We undertook a systematic review and meta-analysis
to evaluate he diagnostic accuracy of available rapid diagnostic tests (RDT) and laboratory based EIA assays in
detecting antibodies to HCV.
Methods: We used the PRISMA checklist and Cochrane guidance to develop our search protocol. The search strategy
was registered in PROSPERO (CRD42015023567). The search focused on hepatitis C, diagnostic tests, and diagnostic
accuracy within eight databases (MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, Science Citation
Index Expanded, Conference Proceedings Citation Index-Science, SCOPUS, Literatura Latino-Americana e do Caribe em
Ciências da Saúde and WHO Global Index Medicus. Studies were included if they evaluated an assay to determine the
sensitivity and specificity of HCV antibody (HCV Ab) in humans. Two reviewers independently extracted data and
performed a quality assessment of the studies using the QUADAS tool. We pooled test estimates using the
DerSimonian-Laird method, by using the software R and RevMan. 5.3.
Results: A total of 52 studies were identified that included 52,673 unique test measurements. Based on five studies, the
pooled sensitivity and specificity of HCV Ab rapid diagnostic tests (RDTs) were 98% (95% CI 98-100%) and 100% (95% CI
100-100%) compared to an enzyme immunoassay (EIA) reference standard. High HCV Ab RDTs sensitivity and specificity
were observed across screening populations (general population, high risk populations, and hospital patients) using
different reference standards (EIA, nucleic acid testing, immunoblot). There were insufficient studies to undertake
subanalyses based on HIV co-infection. Oral HCV Ab RDTs also had excellent sensitivity and specificity compared to blood
reference tests, respectively at 94% (95% CI 93-96%) and 100% (95% CI 100-100%). Among studies that assessed individual
oral RDTs, the eight studies revealed that OraQuick ADVANCE® had a slightly higher sensitivity (98%, 95% CI 97-98%)
compared to the other oral brands (pooled sensitivity: 88%, 95% CI 84-92%).
Conclusions: RDTs, including oral tests, have excellent sensitivity and specificity compared to laboratory-based methods
for HCV antibody detection across a wide range of settings. Oral HCV Ab RDTs had good sensitivity and specificity
compared to blood reference standards.
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Background
Hepatitis C is a liver disease caused by the hepatitis C
virus (HCV) that causes acute and chronic infection [1, 2].
An estimated 71 million people had chronic hepatitis C
infection worldwide in 2015 [3]. Viral hepatitis caused
1.34 million deaths in 2015, a number comparable to
deaths caused by tuberculosis and higher than those
caused by HIV [3]. The introduction of direct-acting anti-
virals (DAAs) has led to a sustained virological response
(SVR) in greater than 90% of treated individuals [4, 5].
DAAs are now recommended by the World Health
Organization (WHO) [1] and many other HCV treatment
guidelines [1]. DAAs will not only improve SVR rates but
also may simplify HCV management algorithms and allow
smaller health facilities to manage HCV-infected individ-
uals [6]. Despite the availability of effective treatment,
most HCV-infected individuals remain undiagnosed and
untreated [7]. Left untreated, approximately 15–30% of in-
dividuals with chronic HCV infection progress to cirrho-
sis, leading to end-stage liver disease and hepatocellular
carcinoma [1, 2].
In February 2016 the WHO updated the guidelines for
the screening, care, and treatment of persons with chronic
hepatitis C infection [1]. These guidelines included recom-
mendations on whom to screen for HCV and how to con-
firm HCV infection, but not which tests are optimal for
initial screening. Advances in HCV detection technology
create new opportunities for enhancing screening, referral,
and treatment. Previous systematic reviews on HCV infec-
tion have focused on treatment response [8, 9], clinical
complications [10], and epidemiology [11, 12]. Two previ-
ous systematic reviews on hepatitis C testing have focused
on evaluating point-of-care tests compared to EIAs and
other reference tests [13, 14]. We have undertaken a fur-
ther systematic review and meta-analysis to generate
pooled sensitivity and specificity of rapid diagnostic tests
used to detect HCV antibody (HCV Ab), and to inform
the development of recommendations on serological test-
ing in the 2017 WHO testing guidelines [15].
Methods
Research question
The main purpose of the review was to assess the diag-
nostic accuracy of available assays for detecting HCV Ab
in persons identified for hepatitis C testing. The research
question was structured in a PICO format (ie. popula-
tion, intervention, comparisons and outcome).
P: Persons identified for HCV testing; I: Rapid diag-
nostic tests and enzyme immunoassays for HCV Ab de-
tection; C: 1), EIA (with a subanalysis based on the last
10 years); 2), NAT (nucleic acid testing); 3), Immunoblot
or similar assay; 4), A combination of 1,2,3 above; O:
Diagnostic accuracy [Sensitivity (SE), Specificity (SP),
Positive predictive value (PPV), Negative predictive value
(NPV), True Negative, True Positive (TP), False negative
(FN), and False positive (FP)].
Search strategy and identification of studies
Search strategies were developed by a medical librarian
with expertise in designing systematic review searches. Our
search algorithm consisted of the following components:
hepatitis C, diagnostic tests, and diagnostic accuracy. We
searched MEDLINE (OVID interface, 1946 onwards),
EMBASE (OVID interface, 1947 onwards), the Cochrane
Central Register of Controlled Trials (Wiley interface,
current issue), Science Citation Index Expanded (Web of
Science interface, 1970 onwards), Conference Proceedings
Citation Index-Science (Web of Science interface, 1990 on-
wards), SCOPUS (1960 onwards), Literatura Latino-
Americana e do Caribe em Ciências da Saúde (LILACS)
(BIREME interface) and WHO Global Index Medicus. The
search was supplemented by searching for ongoing studies
in WHO’s International Clinical Trials Registry. The litera-
ture search was limited to English language and human
subjects that available until April 30th, 2015. In addition to
searching databases, we contacted individual researchers
and authors of major trials to address whether any relevant
manuscripts are in preparation or in press. The references
of published articles found in the above databases were
searched for additional pertinent materials.
Study selection proceeded in three stages: 1) titles/ab-
stracts were screened by a single reviewer according to
standard inclusion and exclusion criteria; 2) full manu-
scripts were obtained and evaluated by two independent
reviewers to include or not; 3) two independent re-
viewers extracted all data. Differences were resolved by a
third independent reviewer.
Selection criteria
The inclusion criteria included the following: primary pur-
pose was HCV Ab test evaluation, reported sensitivity and
specificity of HCV Ab test kits, and studies published be-
fore May 2015. We included observational and rando-
mised control trial (RCT) studies that provided original
data from patient specimens. Studies that only reported
sensitivity or specificity, conference abstracts, comments
or review papers, panel studies, or those that only used
reference assays for positive samples were excluded. In
this manuscript, a hepatitis panel refers to a laboratory
series test in which use the blood with confirmed hepatitis
C serostatus to assess the accuracy of a testing kit.
Data extraction
Information on the following variables were extracted
from each individual study: first author, total sample
size, country (and city) of sampling, sample type (oral
fluid, finger prick, venous blood), point-of-care (POC,
defined as being able to give a result within 60 min and
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having the results to guide clinical management in the
same encounter), eligibility criteria, reference standard,
manufacturer, raw cell numbers (true positives, false
negatives, false positives, true negatives), antibody-
antigen combo (yes or no), sources of funding, reported
conflict of interest, and study population (general popu-
lation, high risk population and hospitalized population).
The high risk population groups include men who have
sex with men, sex workers and their clients, transgender
people, people who inject drugs and prisoners and other
incarcerated people [16]. The hospitalized population
was defined as those admitted to a hospital for medical
care or observation. We also verified whether assays
evaluated in the studies were currently on the market
(as of June 1st, 2017), and if this was the case, we also
reported the available version of the testing kit (Table 1).
Assessment of methodological quality
Study quality was evaluated using the QUADAS-2 tool
[17] and the STARD checklist [18]. QUADAS includes
domains to evaluate bias in the following categories: risk
of bias (patient selection, index test, reference standard,
flow, and timing); applicability concerns (patient selec-
tion, index test, reference standard). The STARD check-
list consists of a checklist of 25 items and flow diagram
that authors can use to ensure that all relevant informa-
tion is present.
Data analysis and synthesis
Data synthesis
Data were extracted to construct 2 × 2 tables. By com-
paring with reference standard results, the index test re-
sults were categorized as a true positive, a false positive,
a false negative, or a true negative. Indeterminate test re-
sults were not included in pooled analyses.
Statistical analysis
To estimate test accuracy, we calculated sensitivity and
specificity for each study and pooled statistics, along
with 95% confidence intervals [19]. We pooled test esti-
mates using the DerSimonian-Laird method, a bivariate
random effect model. We did further subanalyses based
on reference standard (EIA alone; NAT or immunoblot;
EIA, NAT, or immunoblot), brand, sample type, and
combination test. We performed all statistical analysis
(including heterogeneity, through Q test) using the soft-
ware R and RevMan 5.3.
Results
Study selection
A total of 11,163 citations were identified, and 6163 dupli-
cates were removed. Each of the 5000 unique citations was
examined. A total of 52 research studies were included in
the final analysis (Fig. 1) [8, 16, 19–68]. Of the 52 studies,
32 studies evaluated the accuracy of 30 different rapid diag-
nostic tests (RDTs) [19–50], of which 5 evaluated RDTs
compared to EIA alone [25, 26, 31, 34, 49], 13 compared
RDT results to NAT or immunoblot [19–22, 27, 29, 32, 37,
42, 43, 45, 47, 50], and 14 focused on evaluating RDT by
comparing with the results of EIA or immunoblot or NAT
[23–26, 30, 34, 35, 38, 39, 41, 44, 48, 49, 51]. Eleven studies
evaluated the diagnostic accuracy of oral fluid RDTs [22,
24, 27, 29, 33, 34, 43–45, 47, 52].
There were insufficient data to undertake a subanalysis
based on HIV co-infection or other co-infections.
Study characteristics
Of the 52 included studies, nine were published before
2000 [37, 38, 42, 53–58], 12 studies reported evaluation
using oral fluid samples, and 34 studies evaluated POC
tests. Of the 52 studies, 41 different brands of testing
kits were evaluated (Table 1).
Assessment of the quality of the studies
All studies used a cross-sectional or case–control design.
The risk of bias in patient selection, index test, or refer-
ence standard was assessed using QUADAS-2 (Table 2).
Among the included studies, 25 had at least one category
that was considered high risk [19, 22, 25–28, 30, 31, 34,
36–39, 41, 45–50, 53, 55, 56, 58–62]. The risk of bias in
patient selection usually came from a poor description of
patient selection and clinical scenario. Bias in the index
test was primarily due to a lack of reported blinding while
reading test results. Bias in the reference standard was due
to the use of multiple reference standards (EIA, NAT,
and/or immunoblot). Bias in the flow and timing was pri-
marily due to a lack of reported details.
Diagnostic accuracy
Overall clinical performance of assays
The 52 included studies contributed 127 data points from
52,273 unique test measurements. Some studies contrib-
uted additional data points by comparing the accuracy of
two or more tests, reporting data from multiple study
sites, or reporting the accuracy of a test in more than one
type of specimen. The sample sizes of the included studies
ranged from 37 to 17,894. Sensitivities of included studies
ranged from 22 to 100%, and specificities ranged from 77
to 100%. The overall pooled sensitivity and specificity for
all tests were 97% (95% CI: 97%–98%) and 99% (95% CI:
98%-99%) respectively. Figure 2 shows estimates of sensi-
tivity and specificity from each study.
Manufacturers and accuracy of RDTs among included
studies
Overall, 32 studies evaluated the accuracy of 30 different
RDTs (Table 3). The most commonly evaluated test kit was
the OraQuick ADVANCE® from OraSure Technologies.
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Table 1 Characteristics of studies focused on evaluating diagnostic accuracy of HCV antibody tests
First author Year Settings Sample type Manufacturer Study
type
Sample
size
POC
(Y/N)
Reference standard Still on the market?
PRODUCT NAME
Al-Tahish et al. 2013 Egypt Venous
blood
HCV one step test
device (ACON
Laboratories, USA),
Fourth- generation
HCV TRI_DOT (J. Mitra
Co, India) and
ImmunoComb II HCV
(Inverness Medical
Innovations, USA)
CS 100 Y PCR Yes Foresight® HCV
EIA test kit; Yes, HCV
TRI_DOT
Bonacini et al. 2001 USA Venous
blood
Ortho Clinical
Diagnostics (Raritan,
NJ, USA)
CS 222 N Chiron IMMUNOBLOT
HCV 3.0 SIA
Not available
Buti et al. 2000 Sprain Serum Not available CS 188 Y IMMUNOBLOT Not avaliable
Caudai et al. 1998 USA Serum or
plasma
samples
ELISA 2nd generation
Abbott Laboratories,
Abbott park, IL, USA)
CS 682 N PCR Not avaliable
Cha et al. 2013 Korea Oral fluids
and serum
OraQuick (OraSure
Technologies, PA USA)
CC 437 Y PCR Yes, The OraQuick®
HCV
Croom et al. 2006 Austria Venous
blood
Monolisa anti-HCV
PLUSVersion 2 EIA
(Bio-Rad, France)
CS 182 N EIA Yes, MONOLISA™
Anti-HCV PLUS Assay
Version 2
da Rosa et al. 2013 Brazil Serum Rapid Test Bioeasy®
(Standard Diagnostics,
Yongin, Korea) and
Imuno-Rapido HCV®
(Wama Diagnostica,
Brazil).
CS 307 Y Architect HCV, PCR Not available for
Rapid Test Bioeasy;
Yes, Imuno-Rapido
HCV
Daniel et al. 2005 India Serum TRI DOT (J. MITRA &Co.
Ltd., New Delhi, India)
CS 2590 Y EIA, IMMUNOBLOT,
PCR
YES, HCV TRI_DOT
Denoyel et al. 2004 France and
Germany
Serum or
plasma
samples
AxSYM HCV 3.0 (other
information is not
available)
CS 5700 N IMMUNOBLOT Yes, AXSYM HCV 3.0
Dokubo et al. 2014 USA Blood HCV Version 3.0 ELISA
(Ortho®)
CS 132 N PCR Yes, ORTHO® HCV 3.0
Elisa
Drobnik et al. 2011 USA Oral fluid OraQuick (OraSure
Technologies, PA USA)
CS 484 Y EIA, IMMUNOBLOT Yes, The OraQuick®
HCV
Eroglu et al. 2000 Turkey Plasma
specimens
ELISA v3.0(Ortho®) CS 160 N PCR Yes, ORTHO® HCV 3.0
Elisa
Feucht et al. 1995 Germany Plasma
specimens
Abbott HCV second-
generation enzyme
immunoassay (other
information is not
available)
CS 262 N IMMUNOBLOT Not avaliable
Gao et al. 2014 USA Serum OraQuick (OraSure
Technologies, PA USA)
CS 289 Y EIA Yes, The OraQuick®
HCV
Hess et al. 2014 USA whole blood DPP HIV-HCV-Syphilis
Assay (Chembio Diag-
nostic Systems, Inc.,
Medford, NY)
CS 948 Y EIA Not avaliable
Hui et al. 2002 Hong kong,
China
Whole blood OraQuick (OraSure
Technologies, PA USA)
CS 197 Y EIA Yes, The OraQuick®
HCV
Ibrahim et al. 2015 Saudi
Arabia
Oral fluid OraQuick (OraSure
Technologies, PA USA)
CC 160 Y PCR Yes, The OraQuick®
HCV
Ivantes et al. 2010 Brazil Whole blood HCV Rapid Test
Bioeasy (Bioeasy
Diagnostica Ltda,
Minas Gerais, Brazil)
CS 71 Y CLIA Not available
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Table 1 Characteristics of studies focused on evaluating diagnostic accuracy of HCV antibody tests (Continued)
First author Year Settings Sample type Manufacturer Study
type
Sample
size
POC
(Y/N)
Reference standard Still on the market?
PRODUCT NAME
Jewett et al. 2012 USA Oral fluids Chembio DPP HCV
test (Chembio
Diagnostic
Systems,USA) and
Rapid HIV/HCV
antibody test
(Medmira Laboratories,
Canada)
CS 407 Y IMMUNOBLOT/NAT Not available for
Chembio DPP HCV
test; Yes, Multiplo
HBc/HIV/HCV
Kant et al. 2012 Germany Whole blood Toyo anti-HCV test
(Turklab, Izmir, Turkey)
CS 185 Y Architect HCV Yes, anti-HCV TEST
Kaur et al. 2000 India Serum HCV Bidot (J. Mitra Co.,
India)
CS 2754 Y EIA 3rd generation YES, DIAGNOS HCV
BI-DOT
Kim et al. 2013 Republic of
Korea
Serum GENEDIA® HCV Rapid
LF (Green Cross
medical science corp.,
Korea)
CC 200 Y IMMUNOBLOT Yes, GENEDIA HCV
Rapid LF test kit
Kosack et al. 2014 Germany Serum The ImmunoFlow HCV
test (Core
Diagnostics,United
Kingdom)
CS 81 Y IMMUNOBLOT Yes, ImmunoFlow
HCV
Lakshmi et al. 2007 India Blood Beijing United
Biomedical, Ortho
Clinical Diagnostics,
General Biologicals;
other information is
not avaliable
CS 69 N PCR Not avaliable
Larrat et al. 2012 France FSB
(fingerstick
blood) and
oral fluid
cEIA: the Monolisa®
HCV-Ag-Ab-ULTRA
(Bio-Rad, Marnes-la-
Coquette, France)
CC 201 Y PCR Yes, MONOLISA™ HCV
Ag-Ab ULTRA
Lee et al. 2010 USA Oral fluid OraQuick (OraSure
Technologies, PA USA)
CS 572 Y EIA, IMMUNOBLOT Yes, The OraQuick®
HCV
Lee et al. 2011 USA Serum,
plasma,
venous
blood,
figerstick
blood and
oral fluid
Or Quick (OraSure
Technologies, PA USA)
CS 2183 Y EIA, IMMUNOBLOT,
PCR
Yes, The OraQuick®
HCV
Lee et al. 2011 USA Oral fluid OraQuick (OraSure
Technologies, PA USA)
CS 2180,
2178
Y EIA Yes, The OraQuick®
HCV
Maity et al. 2012 India Serum J Mitra & Co. Pvt. Ltd.,
SPAN Diagnostics Ltd.
and Standard
Diagnostics, INC, other
information is not
available
CC 100 Y EIA Not avaliable
Montebugnoil
et al.
1999 Italy whole blood Anti-HCV Ab rapid test
(1st IRP 75/537 by
Thema Ricerca, WHO
Geneva)
CC 100 Y EIA, IMMUNOBLOT Not avaliable
Mvere et al. 1996 Zimbabwe Serum HCV-SPOT (Genelabs
Diagnostics,
Singapore)
CS 206 Y EIA 2nd generation,
INNO-LIA HCV ab III
Not avaliable
Nalpas et al. 1992 France Serum Ortho Diagnostics,
other information is
not available
CS 62 N PCR Not avaliable
Njouom et al. 2006 Cameroon Plasma ImmunoComb® II HCV
assay (Orgenics Ltd.,);
CS 329 Y EIA 3rd generation,
PCR
Not avaliable
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Table 1 Characteristics of studies focused on evaluating diagnostic accuracy of HCV antibody tests (Continued)
First author Year Settings Sample type Manufacturer Study
type
Sample
size
POC
(Y/N)
Reference standard Still on the market?
PRODUCT NAME
ImmunoComb® II HCV
assay (Orgenics Ltd.,
Not reported
manufacturer located
country)
Nyirenda et al. 2008 Malawi Serum Monoelisa HCV Ag/Ab
ultra-microplate EIA
(Bio-Rad, France)
CS 202 Y EIA Yes, MONOLISA™ HCV
Ag-Ab ULTRA
O’Connell
et al.
2013 USA Plasma,
whole blood
(normal) and
whole blood
(cold storge)
OraQuick (OraSure
Technologies, PA USA);
CORE (CORE
Diagnostics, United
Kingdom); Axiom
(Axiom Diagnostics,
Burstadt,Germany);
FirstVue (AT First
Diagnostic,
Woodbury,NY, USA)
and Instant View
Cassette (Alfa Scientific
Designs, Poway)
CC 674,
168
Y EIA, IMMUNOBLOT,
and when available
viral load)
Yes, The OraQuick®
HCV; Yes, Core HCV;
Not avaliable for
Axiom; Yes, FirstVue™
Hepatitis “C” Rapid
Test; Yes, Instant-
view™ Hepatitis C
Virus (HCV) Serum
Test
O’Flynn et al. 1997 Ireland,
Germany,
UK
Plasma and
serum
AxSYM (Abbott
Laboratories, other
information is not
available)
CC 5554,
1421,
643
N ABBOTT MATRIX HCV,
Chiron IMMUNOBLOT
HCV 2.0 or 3.0
Yes, AXSYM HCV 3.0
Park et al. 2012 Korea Serum Vitros anti-HCV assay
kits (Ortho-Clinical
Diagnostics, Bucking-
hamshire, UK) and
Elecsys (Roche Diag-
nostics GmbHMann-
heim, Germany)
CS 1008 N IMMUNOBLOT HCV 3.0
and Cobas Ampliprep/
Taqman HCV RNA
Not avaliable
Poovorawari
et al.
1994 Thailand Serum HCV-SPOT assay
(Genelabs Diagnostics
Pty Ltd., Singapore)
CS 192 Y EIA 2nd generation or
IMMUNOBLOT
Not avaliable
Prayson et al. 1993 USA Serum C100-3 HCV EIA
(Abbott Laboratories,
other information is
not available)
CS 123 N IMMUNOBLOT 2.0 Not avaliable
Rihn et al. 2000 France serum MATRIX hcv2 (Abbott
Laboratories, other
information is not
available)
CS 146 N PCR Not avaliable
Scalioni Lde
et al.
2014 Brazil Serum,whole
blood and
oral fluid
WAMA Imuno-Rápido
HCV Kit (WAMA Diag-
nóstica, Brazil); Bioeasy
HCV Rapid Test,
(Bioeasy Diagnóstica
Ltd., Brazil) and Ora-
Quick (OraSure Tech-
nologies, PA USA)
CS 194 or
172
Y PCR Yes, Imuno-Rapido
HCV; Not avaliable for
Rapid Test Bioeasy;
Yes, The OraQuick®
HCV
Smith et al. 2011 USA Whole blood,
oral fluid
Multiplo Rapid HIV/
HCV Antibody Test
(MedMira, Canada);
Chembio DPP HCV
test (Chembio
Diagnostic Systems,
USA) and OraQuick
(OraSure Technologies,
USA)
CS 476,
385,
432,
549,
266
Y MEIA/EIA/CLIA,
IMMUNOBLOT
Yes, Multiplo HBc/HIV/
HCV; Not avaliable for
Chembio DPP HCV
test; Yes, The
OraQuick® HCV
Smith et al. 2011 USA Oral fluid and
blood
Multiplo Rapid HIV/
HCV Antibody Test
CS 1081 Y Chiron IMMUNOBLOT
HCV 3.0 SIA; Bayer
Yes, Multiplo HBc/HIV/
HCV; Not avaliable for
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Table 1 Characteristics of studies focused on evaluating diagnostic accuracy of HCV antibody tests (Continued)
First author Year Settings Sample type Manufacturer Study
type
Sample
size
POC
(Y/N)
Reference standard Still on the market?
PRODUCT NAME
(MedMira, Canada);
Chembio DPP HCV
test (Chembio
Diagnostic Systems,
USA)
Advia Centaur HCV
Chemiluminescent
immunoassay
Chembio DPP HCV
test
Sommese
et al.
2014 Italy Blood CMIA assays (Abbott
Diagnostics,
Wiesbaden, Germany)
CS 17,894 N INNO-LIA
(Innogenetics, Ghent,
Belgium), NAT
Not avaliable
Tagny et al. 2014 Cameron Plasma HCV Ag/Ab
combination assay
(Monolisa HCV Ag-Ab
Ultra, BioRad, Marnes
La Coquette, France)
CS 1998 Y EIA Yes, MONOLISA™ HCV
Ag-Ab ULTRA
Vrielink et al. 1996 Netherlands Blood Abbott HCV EIA 3.0
(Abbott laboratories,
Murex anti-HCV VK47
(Murex Diagnostic)
and Ortho HCV 3.0
elisa (Ortho Diagnostic
Systems; other infor-
mation is not available
CS 403,
212,
253 03
1055
N PCR Not available for
Abbott HCV EIA 3.0;
Yes, Murex anti-HCV
(version 4); Yes, OR-
THO® HCV 3.0 Elisa
Vrielink et al. 1995 Netherlands Blood Monolisa anti-HCV
new antigens (Sanofi
Diagnostics Pasteur),
Abbott HCV EIA 3.0
(Abbott Laboratories);
other information is
not available
CS 403,
212,
253
N PCR Not avaliable
Yang et al. 2011 China Serum AxSYM HCV 3.0
(Abbott Laboratories),
Murex Ag/Ab test
(Abbott Laboratories);
other information is
not available
CC 101 or
100
N HCV RNA test (COBAS
AMPLICOR Hepatitis C
Virus Test, version 2.0
Yes, AXSYM HCV 3.0;
Not avaliable for
Murex Ag/Ab test
Yang et al. 2013 China Serum Elecsys anti-HCV II
(Roche Diagnostics
GmbH), Architect anti-
HCV (Abbott) and
Vitros anti-HCV (Ortho-
Clinical Diagnostics),
other information is
not available
CS 859 or
167
N IMMUNOBLOT 3.0 test
or the Realtime HCV
RNA assay
Yes, Elecsys® Anti-HCV
II; Yes, ARCHITECT
i1000SR I; Not avail-
able for Ortho-Clinical
Diagnostics
Yarri et al. 2006 Israel Serum and
oral fluid
ImmunoComb II HCV
(Inverness Medical
Innovations, USA)
CS 37 Y PCR Not avaliable
Yoo et al. 2015 South
Korea;
China;
China/
Taiwan;
Thailand;
Australia;
Malaysia;
Indonesia
Serum Elecsys® Anti-HCV II
assay; (Roche Diagnos-
tics GmbH, other infor-
mation is not
avaliable)
CS 7726 Y 1 or more of the
following comparator
assays at 9 centers:
ARCHITECTTM Anti-
HCV; Serodia®-HCV Par-
ticle Agglutination;
Vitros® ECi Anti-HCV;
Elecsys® Anti-HCV;
ADVIA Centaur® HCV;
InTec® HCV EIA; or Liv-
zon® Anti-HCV.
Yes, Elecsys® Anti-HCV
II
Yuen et al. 2001 China Serum SM-HCV Rapid Test
(SERO-Med
Laborspezialita¨ten
GmbH, Eichsta ¨tt,
Germany)
CC 290 Y EIA, PCR Not avaliable
Notes: CC case–control study, CS cross-sectional study
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Pooled test accuracy for RDT versus EIA alone
Overall, five studies evaluated RDTs compared to the
EIA alone, with a total sample of 15,943. Of the five
studies, sample sizes ranged from 197 to 2754, sensi-
tivities ranged from 83 to 100%, and specificities
ranged from 99 to 100%. The pooled sensitivity and
specificity were 98% (95% CI 98%-100%) and 100%
(95% CI 100%-100%), respectively, while heterogeneity
was observed in the included studies (P < 0.001)
(Table 3, Additional file 1).
For the three studies that were conducted within
the last 10 years [25, 49, 51], the total sample size
was 12,992, with pooled sensitivity and specificity of
99% (95%CI 99%-100%) and 100% (95%CI 100%-
100%), respectively.
RDT accuracy compared to NAT or immunoblot
Overall, 13 studies evaluated RDTs compared to NAT or
immunoblot [19–22, 27, 29, 32, 37, 42, 43, 45, 47, 50],
with a total sample of 7083. Among these studies, sam-
ple sizes ranged from 36 to 549, sensitivities ranged from
76 to 100%, and specificities ranged from 77% to 100%.
The pooled sensitivity and specificity were 93% (95% CI
91%-95%) and 98% (95% CI 98%- 99%), respectively,
while heterogeneity was observed in the included studies
(P < 0.001) (Table 3, Additional file 2).
RDT test accuracy compared to EIA, NAT or Immunoblot
Overall, 14 studies evaluated RDTs by referencing to
EIA with NAT and/or immunoblot [25, 26, 31, 33–35,
38, 39, 41, 45, 48, 49], with a total sample of 42,212. Of
Fig. 1 PRISMA flow diagram outlining study selection examining the diagnostic accuracy of HCV antibody tests
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Table 2 Quality assessment by QUADAS-2 of the included studies
Reports Bias assessment/Risk of bias Acceptability concerns
Patient selection Index test Reference Standard Flow and timing Patient selection Index test Reference Standard
Al-Tahish et al. 2013 UC LR LR LR LR LR LR
Bonacini et al. 2001 HR LR LR LR LR LR LR
Buti et al. 2000 UC UC LR LR HR LR LR
Caudai et al. 1998 HR LR LR LR UC LR LR
Cha et al. 2013 HR LR LR LR UC LR LR
Croom et al. 2006 LR LR LR UC LR LR LR
da Rosa et al. 2013 HR UC LR LR HR UC LR
Daniel et al. 2005 LR LR LR LR LR LR LR
Denoyel et al. 2004 UC LR LR LR UC LR HR
Drobnik et al. 2011 LR UC LR UC LR UC LR
Eroglu et al. 2000 LR LR LR LR LR LR LR
Feucht et al. 1995 HR LR LR LR HR LR LR
Gao et al. 2014 LR LR LR HR LR LR LR
Hess et al. 2014 LR HR LR LR LR HR LR
Hui et al. 2002 HR LR HR LR HR LR HR
Ivantes et al. 2010 LR UC HR LR LR LR HR
Jewett et al. 2012 LR LR LR LR LR LR LR
Dokuboa et al. 2014 UC LR LR LR UC LR LR
Kant et al. 2012 HR UC HR LR HR UC HR
Kaur et al. 2000 LR UC HR LR LR LR LR
Kim et al. 2013 UC LR LR LR UC LR LR
Kosack et al. 2014 HR LR LR LR HR LR LR
Lakshmi et al. 2007 UC LR LR UC HR LR LR
Larrat et al. 2012 LR LR LR LR LR LR LR
Lee et al. 2010 LR UC LR LR LR UC LR
Lee et al. 2011 HR UC LR LR LR LR LR
Maity et al. 2012 HR UC HR LR HR UC HR
Montebugnoil et al. 1999 HR LR LR LR HR LR LR
Mvere et al. 1996 HR LR LR LR HR LR LR
Nalpas et al. 1992 HR LR LR UC HR LR LR
Njouom et al. 2006 HR UC LR LR HR UC LR
Nyirenda et al. 2008 LR UC LR LR LR LR LR
O’Connell et al. 2013 HR LR HR LR HR LR LR
O’Flynn et al. 1997 UC LR LR UC LR LR LR
Park et al. 2012 UC LR LR UC LR LR LR
Poovorawari et al. 1994 LR UC LR LR LR LR LR
Prayson et al. 1993 UC LR LR UC UC LR LR
Rihn et al. 2000 UC LR LR UC UC LR LR
Scalioni et al. 2014 UC LR LR UC UC LR LR
Smith et al. 2011 LR LR LR LR LR LR LR
Smith et al. 2011 HR LR LR LR HR LR LR
Sommese et al. 2014 LR LR LR LR LR LR LR
Lee et al. 2010_2 LR LR LR LR LR LR LR
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the 14 studies, sample sizes ranged from 168 to 2754,
sensitivities ranged from 29 to 100%, and specificities
ranged from 90 to 100%. The pooled sensitivity and
specificity were 97% (95% CI 96% -98%) and 100% (95%
CI 100%-100%), respectively, while heterogeneity was
observed in the included studies (P < 0.001) (Table 3,
Additional file 3).
Pooled test accuracy for oral versus blood samples
EIAs using oral fluid samples
Overall, 11 studies compared the accuracy of EIAs using
oral fluid samples to a blood sample as a reference, with
a total sample size of 12,370 [22, 24, 27, 29, 33, 34, 43–
45, 47, 52]. Of the 12 studies, sample sizes ranged from
37 to 2176, sensitivities ranged from 72 to 100%, and
specificities ranged from 91 to 100%. The pooled sensi-
tivity and specificity were 94% (95% CI 93%-96%) and
100% (95% CI 99%-100%), respectively. Heterogeneity
was observed in the included studies (P < 0.001) (Table 3,
Additional file 4).
Blood samples
Overall, 47 studies used blood samples for evaluations, with
a total sample of 90,008. Sample sizes ranged from 37 to
17,894, sensitivities ranged from 29 to 100%, and specific-
ities ranged from 18 to 100%. The pooled sensitivity and
specificity were 98% (95% CI 97%-98%) and 98% (95% CI
98%- 98%), respectively. Heterogeneity was observed in the
included studies (P < 0.001) (Table 3, Fig. 3).
Pooled test accuracy for OraQuick versus other brands on
oral kits
OraQuick
Overall, eight studies reported sensitivity and specificity
of OraQuick (OraSure Technologies, PA, USA), with a
total sample of 9024 [22, 24, 27, 33–35, 43, 45]. The
sample size of these studies ranged from 172 to 2183,
sensitivities ranged from 90% to 100%, and specificities
ranged from 95% to 100%. The pooled sensitivity and
specificity were 98% (95% CI 97%-99%) and 100% (95%
CI 90%-100%), respectively. Heterogeneity was ob-
served in the included studies (P < 0.001) (Table 3,
Additional file 5).
Overall, six studies reported sensitivity and specificity
for other three brands of oral kits [29, 43–45, 47, 52],
with a total sample of 6652. The sample size of these
studies ranged from 37 to 1081, sensitivities ranged from
72 to 100%, and specificities ranged from 91 to 100%.
The pooled sensitivity and specificity were 88% (95% CI
84%-92%) and 99% (95% CI 99%- 100%), respectively,
while heterogeneity was observed between the included
studies (P < 0.001) (Table 3, Additional file 6).
Other findings
Our study further found that the overall sensitivity
and specificity of studies conducted among general
populations were 95% (95% CI 94%-96%) and 99%
(95% CI 98%-99%), among high risk populations were
97% (95% CI 96%-98%) and 94% (95% CI 94%-95%),
and among hospital patients were 97% (95% CI 96%-
98%) and 100% (95% CI 100%-100%), respectively.
The overall sensitivity and specificity of the antibody
and antigen combo test were 86% (95% CI 79%-99%)
and 99% (95% CI: 98%-100%).
GRADE approach (Grading of Recommendations,
Assessment, Development and Evaluation to assessing
overall quality of evidence
GRADE for RDT versus EIA
HCV Ab RDTs showed comparable sensitivity and
specificity compared to that of EIAs. Among the five
studies that evaluated RDTs versus EIA, 15,943 of
samples were evaluated, and moderate risk of bias
was observed (Table 4), but there was a consistent
high level of specificity. Since the unit of the analysis
varied among studies (Table 4), indirectness was
Table 2 Quality assessment by QUADAS-2 of the included studies (Continued)
Reports Bias assessment/Risk of bias Acceptability concerns
Patient selection Index test Reference Standard Flow and timing Patient selection Index test Reference Standard
Ibrahim et al. 2015 HR LR LR LR HR LR LR
Tagny et al. 2014 LR UC HR LR LR UC HR
Vrielink et al. 1995 UC LR LR LR UC LR LR
Vrielink et al. 1995_2 UC LR LR LR HR LR LR
Yang et al. 2011 UC LR LR LR UC LR LR
Yang et al. 2013 LR LR LR UC LR LR LR
Yarri et al. 2006 HR LR LR LR HR LR LR
Yoo 2015 UC LR LR HR UC LR LR
Yuen et al. 2001 HR LR LR LR HR LR LR
N;otes: LR low risk, HR high risk, UC unclear risk
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observed. In addition, the overall strength of the
pooled evaluation was moderate, with pooled sensitiv-
ity and specificity of 99% (95% CI 98%-100%) and
100% (95% CI 100%-100%), respectively. Under the
pre-test probability of 5%, the post-test probability
after a positive test result is 97%, and the post-test
probability after a negative test result is 100%.
GRADE for oral RDT versus blood reference
The use of oral RDTs HCV Ab had comparable sensi-
tivity and specificity compared to blood reference stan-
dards (Additional file 7). For the 12 studies evaluated
oral RDT versus blood reference, 14,547 samples were
evaluated. A moderate risk of bias was observed. Incon-
sistency was present for sensitivity, as the sensitivities
of the included studies varied. But there was a consist-
ent high level of specificity. Since the unit of the ana-
lysis varied with each other among the included studies
(Table 4), indirectness was observed for included stud-
ies. In addition, the overall strength of the pooled
evaluation was moderate, with pooled sensitivity and
specificity of 94% (95% CI 93%-96%) and 100% (95% CI
100%-100%), respectively. Assuming a pre-test prob-
ability of 5%, the post-test probability after a positive
test result was 94%, and the post-test probability after a
negative test result was 100%.
Discussion
There is a global need to expand HCV diagnostic
testing. In this meta-analysis, we found HCV Ab
RDTs, including those using oral fluid, showed a high
overall sensitivity and specificity compared to
laboratory-based EIAs. This extends the literature by
including several new studies that were not included
in prior reviews, including a sub-analysis that focused
on use of RDTs with oral fluid. In addition, the evi-
dence collected from this review was used to inform
recommendations in the 2017 WHO guidelines on
testing for hepatitis B and C [15]. The evidence for
generally high levels of diagnostic accuracy across
most brands from this systematic review and meta-
analysis supported a strong recommendation for the
use of HCV RDTs in WHO testing guidelines [15].
Our data suggest that RDTs can be used for HCV Ab
detection in a wide range of clinical settings. For ex-
ample, for all the included studies, 17 were conducted
among general populations, 20 were among high risk
populations, and 17 were among hospitalized patients
(two studies included two kinds of populations). High
HCV Ab RDTs sensitivity and specificity were observed
across multiple different populations (including general
population, high risk populations, and hospital patients),
which is consistent with previous systematic reviews [13,
14, 63]. The use of an EIA to detect HCV Ab followed
Fig. 2 Sensitivity and specificity of HCV Ab tests included in the
review (n = 52)
The Author(s) BMC Infectious Diseases 2017, 17(Suppl 1):695 Page 49 of 196
Table 3 Manufacturers and accuracy of RDTs among included studies
First author Manufacturer Sample
size
TP FP TN FN SE SP
Montbugnoil et al. Anti-HCV Ab rapid test (1st IRP 75/537 by Thema Ricerca, WHO Geneva) 100 50 1 49 0 100% 98%
O’Connell, R. J.
et al.
Axiom (Axiom Diagnostics, Burstadt,Germany) 674 326 10 329 9 97% 97%
O’Connell, R. J.
et al.
Axiom (Axiom Diagnostics, Burstadt,Germany) 168 77 2 82 7 92% 98%
O’Connell, R. J.
et al.
Axiom (Axiom Diagnostics, Burstadt,Germany) 168 82 5 79 2 98% 94%
Scalioni Lde, P
et al.
Bioeasy HCV Rapid Test, (Bioeasy Diagnóstica Ltd., Brazil) 194 137 0 48 9 94% 100%
Scalioni Lde, P
et al.
Bioeasy HCV Rapid Test (Bioeasy Diagnóstica Ltd., Brazil) 194 111 0 48 35 76% 100%
Scalioni Lde, P
et al.
Bioeasy HCV Rapid Test (Bioeasy Diagnóstica Ltd., Brazil) 194 136 0 48 10 93% 100%
Jewett, A et al. Chembio DPP HCV Test (Chembio Diagnostic Systems, USA) 407 101 3 290 8 93% 99%
Jewett, A et al. Chembio DPP HCV test (Chembio Diagnostic Systems,USA) 400 88 3 294 15 85% 99%
Smith, B. D et al. Chembio DPP HCV test (Chembio Diagnostic Systems, USA) 476 308 12 125 32 91% 91%
Smith, B. D et al. Chembio DPP HCV test (Chembio Diagnostic Systems, USA) 385 264 3 101 17 94% 97%
Smith et al. et al. Chembio DPP HCV test (Chembio Diagnostic Systems, USA) 1081 525 1 543 12 98% 100%
O’Connell, R. J.
et al.
CORE (CORE Diagnostics, United Kingdom) 168 29 1 83 55 35% 99%
O’Connell, R. J
et al.
CORE (CORE Diagnostics, United Kingdom) 168 24 2 82 60 29% 98%
O’Connell, R. J
et al.
CORE (CORE Diagnostics, United Kingdom) 674 323 7 332 12 96% 98%
Maity et al. Diagnostics Ltd. (other information is not available) 300 132 0 168 0 100% 100%
O’Connell, R. J.
et al.
FirstVue (AT First Diagnostic, Woodbury,NY, USA) 168 66 0 84 18 79% 100%
O’Connell, R. J.
et al.
FirstVue (AT First Diagnostic, Woodbury,NY, USA) 168 54 1 83 30 64% 99%
O’Connell, R. J.
et al.
FirstVue (AT First Diagnostic, Woodbury,NY, USA) 674 312 3 336 23 93% 99%
Al-Tahish et al. Fourth- generation HCV TRI_DOT (J. Mitra Co, India) 100 34 15 50 1 97% 77%
Daniel et al. Fourth- generation HCV TRI_DOT (J. Mitra Co, India) 2590 138 24 2427 1 99% 99%
Kim, M. H. et al. GENEDIA® HCV Rapid LF (Green Cross medical science corp., Korea) 100 52 0 34 14 79% 100%
Kaur et al. HCV Bidot (J. Mitra Co., India) 2754 28 0 2722 4 88% 100%
Al-Tahish HCV one step test device (ACON Laboratories, USA) 100 34 15 50 1 97% 77%
Ivantes et al. HCV Rapid Test Bioeasy (Bioeasy Diagnostica Ltd., Brazil) 71 30 3 38 0 100% 93%
da Rosa et al. HCV Rapid Test Bioeasy® (Standard Diagnostics, South Korea) 307 100 0 204 3 97% 100%
Poovoran et al. HCV-SPOT assay (Genelabs Diagnostics Pty Ltd., Singapore) 192 41 11 139 1 98% 93%
Mvere et al. HCV-SPOT assay (Genelabs Diagnostics Pty Ltd., Singapore) 206 10 4 191 1 91% 98%
Njouom et al. Hexagon® HCV (Not reported manufacturer located country) 329 160 17 151 1 99% 90%
Al-Tahish et al. ImmunoComb II HCV (Inverness Medical Innovations, USA) 100 34 14 51 1 97% 78%
Yarri et al. ImmunoComb II HCV (Inverness Medical Innovations, USA) 37 18 4 15 0 100% 79%
Yarri et al. ImmunoComb II HCV (Inverness Medical Innovations, USA) 37 18 1 18 0 100% 95%
Njouom et al. ImmunoComb® II HCV assay (Orgenics Ltd., not reported manufacturer located
country)
329 103 0 168 58 64% 100%
da Rosa et al. Imuno-Rapido HCV® (Wama Diagnostica, Brazil). 307 100 0 204 3 97% 100%
Instant View Cassette (Alfa Scientific Designs, Poway, CA, USA) 674 321 3 336 14 96% 99%
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Table 3 Manufacturers and accuracy of RDTs among included studies (Continued)
First author Manufacturer Sample
size
TP FP TN FN SE SP
O’Connell, R. J.
et al.
O’Connell, R. J.
et al.
Instant View Cassette (Alfa Scientific Designs, Poway, CA, USA) 168 68 3 81 16 81% 96%
O’Connell, R. J.
et al.
Instant View Cassette (Alfa Scientific Designs, Poway, CA, USA) 168 46 1 83 38 55% 99%
Maity et al. J Mitra Co. India other information is not available) 300 120 0 174 6 95% 100%
Jewett, A et al. Rapid HIV/HCV antibody test (Medmira Laboratories, Canada) 374 80 0 274 20 80% 100%
Nyirenda et al. Monoelisa HCV Ag/Ab ultra-microplate EIA (Bio-Rad, France) 202 2 7 186 7 22% 96%
Tagny et al. Monolisa HCV Ag-Ab Ultra, (BioRad, France) 1998 26 28 1929 15 63% 99%
Smith et al. Multiplo Rapid HIV/HCV Antibody Test (MedMira, Canada) 1081 474 1 543 63 88% 100%
Smith, B. D et al. Multiplo Rapid HIV/HCV Antibody Test (MedMira, Canada) 432 303 8 40 81 79% 83%
Cha, Y. J. et al. OraQuick (OraSure Technologies, PA USA) 437 134 0 300 3 98% 100%
Cha, Y. J. et al. Architect (Abbott Laboratories, Abbott Park, IL, USA) 400 200 0 200 0 100% 100%
Lee, S. R et al. OraQuick (OraSure Technologies, PA USA) 2183 756 1 1422 1 100% 100%
Lee, S. R et al. OraQuick (OraSure Technologies, PA USA) 2183 755 2 1420 1 100% 100%
Lee, S. R et al. OraQuick (OraSure Technologies, PA USA) 2183 753 2 1421 2 100% 100%
Lee, S. R et al. OraQuick (OraSure Technologies, PA USA) 2183 752 1 1421 2 100% 100%
Lee, S. R et al. OraQuick (OraSure Technologies, PA USA) 2183 739 5 1418 14 98% 100%
O’Connell, R. J
et al.
OraQuick (OraSure Technologies, PA USA) 674 333 1 338 2 99% 100%
O’Connell, R. J
et al.
OraQuick (OraSure Technologies, PA USA) 168 83 1 83 1 99% 99%
O’Connell, R. J
et al.
OraQuick (OraSure Technologies, PA USA) 168 82 0 84 2 98% 100%
Smith, B. D et al. OraQuick (OraSure Technologies, PA USA) 549 375 8 140 26 94% .95%
Smith, B. D et al. OraQuick (OraSure Technologies, PA USA) 266 188 1 72 5 97% 99%
Lee et al. OraQuick (OraSure Technologies, PA USA) 572 122 0 449 1 99% 100%
Lee et al. OraQuick (OraSure Technologies, PA USA) 572 123 0 449 0 100% 100%
Lee et al. OraQuick (OraSure Technologies, PA USA) 572 123 0 449 0 100% 100%
Lee et al. OraQuick (OraSure Technologies, PA USA) 572 123 1 448 0 100% 100%
Lee et al. OraQuick (OraSure Technologies, PA USA) 572 123 1 448 0 100% 100%
Smith et al. OraQuick (OraSure Technologies, PA USA) 1081 533 3 541 4 99% 99%
Drobnik et al. OraQuick (OraSure Technologies, PA USA) 484 92 3 382 7 93% 99%
Stephen R. Lee
et al.
OraQuick (OraSure Technologies, PA USA) 2180 756 1 1422 1 100% 100%
Stephen R. Lee
et al.
OraQuick (OraSure Technologies, PA USA) 2178 755 2 1420 1 100% 100%
Stephen R. Lee
et al.
OraQuick (OraSure Technologies, PA USA) 2178 753 2 1421 2 100% 100%
Stephen R. Lee
et al.
OraQuick (OraSure Technologies, PA USA) 2176 752 1 1421 2 100% 100%
Stephen R. Lee
et al.
OraQuick (OraSure Technologies, PA USA) 2176 739 5 1418 14 98% 100%
Gao et al. OraQuick (OraSure Technologies, PA USA) 1156 16 6 1133 1 94% 99%
Ibrahim OraQuick (OraSure Technologies, PA USA) 160 53 0 100 7 88% 100%
Scalioni Lde,
P_2014
OraQuick (OraSure Technologies, PA USA) 172 108 0 50 14 89% 100%
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by NAT to confirm active infection is standard practice
for diagnosis of HCV infection and recommended by
the US Centers for Disease Control and Prevention and
the WHO [64, 65]. However, despite these recommenda-
tions, HCV Ab EIA assays have not been widely used be-
cause of the complexity of laboratory-based assays, long
turnaround time, high cost and requirements for special-
ized apparatus and trained technicians [13]. To over-
come these barriers, RDTs for HCV Ab screening were
developed [66]. They obviate the need for multiple
follow-up appointments, shorten wait times, and allow
for the simplification and decentralization of testing
(Additional file 8). However, it is essential for policy-
makers, government officials, and health care practi-
tioners engaged in HCV screening, care, and treatment
to be aware that the performance of individual RDTs for
detection of HCV Ab vary widely. Individual diagnostic
accuracy for specific brands should be examined to en-
sure acceptable performance.
Our data suggest that oral fluid RDTs have high sensi-
tivity and specificity. This is consistent with other litera-
ture [67]. Tests that can be used with non-invasive
samples allow testing to be decentralized further and
can be used in outreach settings [68]. Our data suggest
that oral tests have a slightly lower pooled sensitivity
(94%, 95%CI: 93%-96%) compared to blood-based tests
(98%, 95% CI: 97%-98%) but comparable specificity. Oral
HCV Ab RDTs tests may be particularly useful in con-
texts where venepuncture may be difficult, such as sub-
sets of people who inject drugs which have difficult
veins to access.
With the increasing availability of DAAs, countries are
seeking testing kits with high sensitivity and specificity,
in order to allow them to scale up HCV Ab screening,
especially among at-risk populations. The advantages
and disadvantages of EIAs and RDTs are well established
[15]. Performance, cost, and accessibility need to be con-
sidered. Determining which tests to deploy at which
level of the health care system and for what settings
require policy makers to consider the different attributes
of laboratory-based EIA versus blood-based or oral
RDTs. Potential trade-offs include slightly lower accur-
acy for greater uptake and acceptability of testing,
provision of test results, and linkage to care. Each coun-
try needs to decide on which trade-offs or compromises
are acceptable, based not only on disease prevalence and
the health care infrastructure but also on technical, so-
cioeconomic, cultural, behavioral considerations. For ex-
ample, they need to be clear on whether it is acceptable
to buy Test X which is 10% less accurate than Test Y
but is considerably cheaper so that many more people
can be tested. In addition, although oral RDTs are less
accurate than blood-based RDTs, it may be that oral
RDTs will be more acceptable for outreach testing and
accessing at-risk populations and allow the control pro-
grams to identify more HCV cases. In a low prevalence
setting, even a test with 98% specificity can yield more
false positive than true positive results. All these trade-
offs can be modeled to give an estimate of the cost-
effectiveness and potential impact of different strategies
for HCV Ab screening.
Our review also underlines some of the common
methodological problems encountered in evaluating
diagnostic accuracy. Cross-sectional or case–control
designs were used by all 52 included studies, intro-
ducing a potential risk of bias. These studies used a
broad range of reference standards, which makes the
pooled performance data less meaningful. Within the
evaluation of diagnostic accuracy, even cross-
sectional studies in patients with diagnostic uncer-
tainty and direct comparison of test results with an
appropriate reference standard can be considered
high quality [69]. The majority of the included stud-
ies used convenience sampling. In this review, we
excluded panel studies because they are not based
on clinical settings and our purpose was to generate
data that would be relevant in clinical settings as
part of detection of HCV Ab.
Table 3 Manufacturers and accuracy of RDTs among included studies (Continued)
First author Manufacturer Sample
size
TP FP TN FN SE SP
Hess et al. DPP HIV-HCV-Syphilis Assay (Chembio Diagnostic Systems, Inc., Medford, NY). 948 152 6 776 14 92% 99%
Buti et al. Not available 188 135 0 50 3 98% 100%
Yuen et al. SM-HCV Rapid Test (SERO-Med Laborspezialita¨ten GmbH, Eichsta ¨tt, Germany) 290 98 0 189 3 97% 100%
Maity et al. SPAN Diagnostics, Indi, other information is not available 300 132 0 168 0 100% 100%
Kant et al. Toyo anti-HCV test (Turklab, Izmir, Turkey) 185 82 12 90 1 99% 88%
Kosack, C. S. et al. The ImmunoFlow HCV test (Core Diagnostics,United Kingdom) 82 55 0 26 0 100% 100%
Scalioni Lde et al. WAMA Imuno-Rápido HCV Kit (WAMA Diagnóstica, Brazil) 194 119 3 45 27 82% 94%
Scalioni Lde, P
et al.
WAMA Imuno-Rápido HCV Kit (WAMA Diagnóstica, Brazil) 194 134 3 45 12 92% 94%
Hui et al. Not reported 197 91 0 88 18 83% 100%
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Fig. 3 Pooled HCV Ab test accuracy for blood samples (n = 47 studies)
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Most studies that reported HIV or HBV co-infection
only reported the test performance of the kits among all
samples, instead of disaggregated diagnostic accuracy.
There were insufficient data from two studies to under-
take a subanalysis based on HIV co-infection. It may be
important for policymakers to know the diagnostic ac-
curacy of HCV Ab tests among individuals with co-
infections, particularly HIV co-infection [70], and this
requires further research among co-infected individuals.
Our study is subject to several limitations. First, we
included studies conducted among the general popu-
lation, hospital patients, and high risk populations.
Diagnostic performance can be influenced by disease
prevalence and HCV prevalence is variable among
these different populations [71, 72]. Second, we de-
tected substantial heterogeneity that could influence
our confidence in the review findings [73], but ad-
dressed this problem through a series of sub-group
stratified analyses. Third, about 20 brands of RDT
kits were used in the included studies, and their per-
formance varies considerably. This limited our ability
to summarize the accuracy of different brands, with
the exception of comparing OraQuick to other
brands. Another concern is publication bias, as stud-
ies with poor test performance may be less likely to
be published, leading to distorted estimates of accur-
acy [74]. Fourth, since not all HCV RDTs can be per-
formed from oral fluid/capillary whole blood (some
require plasma/serum), and some of them require a
cold chain for storage and transport, the direct
comparison between EIA and RDTs in this meta-
analysis would be less meaningful. Fifth, we should
note that not all test kits are still on the market and
that versions of the tests included in this meta-
analysis may have since changed. Finally, statistical
heterogeneity was present. But is common in meta-
analyses of diagnostic studies. Additional research is
important for understanding why the tests perform
more poorly in certain populations or settings.
Conclusion
RDTs, including oral tests, have excellent sensitivity and
specificity compared to laboratory-based methods for
HCV antibody detection across a wide range of settings.
National policymakers should consider the performance,
cost and accessibility of RDTs into consideration, when
selecting assays for use in their national testing
algorithms.
Additional files
Additional file 1: Pooled test accuracy of HCV Ab RDTs compared to an
EIA reference (5 studies). (DOCX 360 kb)
Additional file 2: Pooled test accuracy of HCV Ab RDTs compared to a
NAT or immunoblot reference (n = 13 studies). (DOCX 621 kb)
Additional file 3: Pooled test accuracy of HCV Ab RDTs compared
to EIA, NAT or immunoblot reference standards (n = 14 studies).
(DOCX 1170 kb)
Additional file 4: Pooled test accuracy for oral HCV Ab RDTs compared
to blood as a reference (n = 11 studies). (DOCX 349 kb)
Table 4 Pooled test accuracy for different testing strategies (n = 52 studies)*
Comparison Pooled SE 95%CI Tau-square P-value
for hetero-geneity
Pooled SP 95%CI Tau-square P-value
for hetero-geneity
RDT versus EIA only (n = 5) 99% 98% 100% <0.001 100% 100% 100% <0.001
RDT versus NAT or Immunoblot (n = 13) 93% 91% 95% <0.001 98% 97% 99% <0.001
RDT versus EIA, NAT or Immunoblot (n = 14) 97% 96% 098% <0.001 100% 100% 100% <0.001
Oral RDT versus blood reference (n = 12) 94% 93% 96% <0.001 100% 100% 100% <0.001
Sample type
Blood samples (n = 45) 98% 97% 98% <0.001 98% 98% 99%
Oral samples (n = 12) 94% 93% 96% <0.001 100% 100% 100% <0.001
Source population
General screening (n = 17) 95% 94% 96% <0.001 99% 98% 99% <0.001
High risk population (n = 19) 97% 96% 98% <0.001 94% 94% 95% <0.001
Hospital patients (n = 16) 97% 96% 98% <0.001 100% 100% 100% <0.001
Antibody and Antigen Combo testing (n = 6) 86% 79% 94% <0.001 99% 98% 100% <0.001
Oral kits brand 100%
OraQuick (n = 8) 98% 97% 99% <0.001 100% 100% 100% <0.001
Other brands (n = 6) 88% 84% 92% <0.001 99% 99% 100% <0.001
Notes: *Studies conducted in both LMIC and high-income countries were not included here
Studies conducted cross these regions were not included here
SE sensitivity, SP specificity
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Additional file 5: Pooled test accuracy for HCV Ab OraQuick kits
(n = 8 studies). (DOCX 414 kb)
Additional file 6: Pooled test accuracy for other brands of oral HCV Ab
test kits (n = 6 studies). (DOCX 406 kb)
Additional file 7: Grade Table. (DOCX 19 kb)
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